» Articles » PMID: 30097071

Homeobox Oncogene Activation by Pan-cancer DNA Hypermethylation

Overview
Journal Genome Biol
Specialties Biology
Genetics
Date 2018 Aug 12
PMID 30097071
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cancers have long been recognized to be not only genetically but also epigenetically distinct from their tissues of origin. Although genetic alterations underlying oncogene upregulation have been well studied, to what extent epigenetic mechanisms, such as DNA methylation, can also induce oncogene expression remains unknown.

Results: Here, through pan-cancer analysis of 4174 genome-wide profiles, including whole-genome bisulfite sequencing data from 30 normal tissues and 35 solid tumors, we discover a strong correlation between gene-body hypermethylation of DNA methylation canyons, defined as broad under-methylated regions, and overexpression of approximately 43% of homeobox genes, many of which are also oncogenes. To gain insights into the cause-and-effect relationship, we use a newly developed dCas9-SunTag-DNMT3A system to methylate genomic sites of interest. The locus-specific hypermethylation of gene-body canyon, but not promoter, of homeobox oncogene DLX1, can directly increase its gene expression.

Conclusions: Our pan-cancer analysis followed by functional validation reveals DNA hypermethylation as a novel epigenetic mechanism for homeobox oncogene upregulation.

Citing Articles

Molecular counting enables accurate and precise quantification of methylated ctDNA for tumor-naive cancer therapy response monitoring.

Ye P, Viens R, Shelburne K, Langpap S, Bower X, Shi J Sci Rep. 2025; 15(1):5869.

PMID: 39966612 PMC: 11836444. DOI: 10.1038/s41598-025-90013-3.


DNA methylation profiling at base-pair resolution reveals unique epigenetic features of early-onset colorectal cancer in underrepresented populations.

Li J, Riggins K, Yang L, Chen C, Castro P, Alfarkh W Clin Epigenetics. 2025; 17(1):11.

PMID: 39844333 PMC: 11753045. DOI: 10.1186/s13148-025-01817-z.


Unveiling epigenetic regulatory elements associated with breast cancer development.

Jardanowska-Kotuniak M, Draminski M, Wlasnowolski M, Lapinski M, Sengupta K, Agarwal A bioRxiv. 2024; .

PMID: 39605637 PMC: 11601335. DOI: 10.1101/2024.11.12.623187.


Pan-cancer exploration of oncogenic and clinical impacts revealed that HOXA9 is a diagnostic indicator of tumorigenesis.

Shenoy U, Basavarajappa D, Kabekkodu S, Radhakrishnan R Clin Exp Med. 2024; 24(1):134.

PMID: 38904676 PMC: 11192824. DOI: 10.1007/s10238-024-01389-x.


Mutation rate heterogeneity at the sub-gene scale due to local DNA hypomethylation.

Mas-Ponte D, Supek F Nucleic Acids Res. 2024; 52(8):4393-4408.

PMID: 38587182 PMC: 11077091. DOI: 10.1093/nar/gkae252.


References
1.
Abate-Shen C . Deregulated homeobox gene expression in cancer: cause or consequence?. Nat Rev Cancer. 2002; 2(10):777-85. DOI: 10.1038/nrc907. View

2.
Vidal E, Sayols S, Moran S, Guillaumet-Adkins A, Schroeder M, Royo R . A DNA methylation map of human cancer at single base-pair resolution. Oncogene. 2017; 36(40):5648-5657. PMC: 5633654. DOI: 10.1038/onc.2017.176. View

3.
Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

4.
Laurent L, Wong E, Li G, Huynh T, Tsirigos A, Ong C . Dynamic changes in the human methylome during differentiation. Genome Res. 2010; 20(3):320-31. PMC: 2840979. DOI: 10.1101/gr.101907.109. View

5.
Vogelstein B, Kinzler K . Cancer genes and the pathways they control. Nat Med. 2004; 10(8):789-99. DOI: 10.1038/nm1087. View